Fair Value Calculator Fair Value Calculator
EN DE

PHYTO (PHYTO) Fair Value & Analysis

IN · Market cap ₹103M

P PHYTO PHYTO · BSE
Price₹23.85
Fair Value₹21.31
Upside-10.6%
Quality43/100
Watch PHYTO for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range ₹16.42 – ₹29.42

Fair value as of: Jul 5, 2026

From 7 valuation models · updated today

Share price −7.8% over the past month.

Price vs Fair Value (12 months)

₹32.28 ₹21.63 Fair Value ₹21.31 Jul 2025 Jul 2026

12‑month range ₹21.63 – ₹32.28 · fair‑value band ₹16.42 – ₹29.42 · the ₹23.85 price screens above the ₹21.31 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

PHYTO (PHYTO) currently trades at ₹23.85, while our model-based Fair Value estimate is ₹21.31 — implying the stock looks roughly 10.6% overvalued today. We read business quality at 43/100 (below-average quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, PHYTO generated revenue of ₹109M at a net margin of -16.5%. Revenue declined 76.6% year over year. It earns a return on equity of -32.9%. Net debt stands at ₹205M. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹16.42 (bear case) to ₹29.42 (bull case); at ₹23.85, the current price sits within that range. The share trades about 32% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Revenue (TTM) ₹109M
Revenue growth (YoY) -76.6%
Net margin -16.5%
Return on equity -32.9%
Free cash flow ₹8.9M FY2025
Operating margin 34.6%
More key figures
EPS (TTM) ₹-4.19
Net debt ₹205M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PHYTO reported revenue of ₹90.7M in FY2025 versus ₹231M in FY2021, a compound −20.9%/yr. Reported net income was −₹18.0M in FY2025.

Revenue −20.9%/yr
FY21 ₹231M
FY22 ₹268M
FY23 ₹148M
FY24 ₹141M
FY25 ₹90.7M
Net income
FY21 ₹2.3M
FY22 ₹2.2M
FY23 −₹33.3M
FY24 −₹9.9M
FY25 −₹18.0M

Is PHYTO fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "PHYTO Fair Value". https://www.fairvalue-calculator.com/stock/PHYTO

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is PHYTO (PHYTO) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹21.31 versus a price of ₹23.85 — about −11% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PHYTO?
Our model-based fair value for PHYTO is ₹21.31 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹23.85.
What is the quality score of PHYTO?
PHYTO has a Quality Score of 43/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of PHYTO (PHYTO)?
PHYTO reported trailing-twelve-month revenue of about ₹109M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of PHYTO?
The net profit margin of PHYTO is about -16.5%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.